The Fly

Novartis’ Sandoz receives positive CHMP opinion for citrate-free HCF adalimumab

Novartis’ Sandoz announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion for marketing authorization for a citrate-free high concentration formulation, or HCF, of its biosimilar Hyrimoz, or adalimumab. The authorization includes all indications covered by the reference medicine: rheumatoid arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis and uveitis. "Upon approval, the adalimumab citrate-free HCF (100 mg/mL) formulation will offer reduced injection volume and potentially decrease the number of injections required for patients who need 80 mg/mL dosing. The HCF formulation will have the same auto-injector as currently offered, aiming for an enhanced yet familiar patient experience," the company stated.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on NVS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More